ASO Author Reflections: The Landmark Series: Randomized Control Trials Examining Perioperative Chemotherapy and Postoperative Adjuvant Chemotherapy for Resectable Colorectal Liver Metastasis

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Odisio BC, Simoneau E, Holmes AA, Conrad CH, Vauthey JN. Fast-track two-stage hepatectomy using a hybrid interventional radiology/operating suite as alternative option to associated liver partition and portal vein ligation for staged hepatectomy procedure. J Am Coll Surg. 2018;227(2):e5–10.

    PubMed  Google Scholar 

  2. 2.

    Kawaguchi Y, Hasegawa K, Tzeng CD, et al. Performance of a modified three-level classification in stratifying open liver resection procedures in terms of complexity and postoperative morbidity. Br J Surg. 2020;107(3):258–267.

  3. 3.

    Kawaguchi Y, Kopetz S, Newhook TE, et al. Mutation status of RAS, TP53, and SMAD4 is superior to mutation status of ras alone for predicting prognosis after resection of colorectal liver metastases. Clin Cancer Res. 2019;25(19):5843–51.

    CAS  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Kawaguchi Y, Vaythey JN. The Landmark Series: randomized control trials examining perioperative chemotherapy and postoperative adjuvant chemotherapy for resectable colorectal liver metastasis. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-08777-z.

  5. 5.

    Bridgewater JA, Pugh SA, Maishman T, et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2020;21(3):398–411.

    CAS  PubMed  PubMed Central  Google Scholar 

  6. 6.

    Kawaguchi Y, Kopetz S, Lillemoe HA, et al. A new surveillance algorithm after resection of colorectal liver metastases based on changes in recurrence risk and RAS mutation status. J Natl Comprehensive Cancer Netw JNCCN. (in press).

Download references

Funding

This research was supported in part by the National Institutes of Health (T32 CA 009599) and the MD Anderson Cancer Center Support Grant, CA016672.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Yoshikuni Kawaguchi MD.

Ethics declarations

Disclosures

Yoshikuni Kawaguchi and Jean-Nicolas Vauthey have no conflicts of interest to disclose.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kawaguchi, Y., Vauthey, J. ASO Author Reflections: The Landmark Series: Randomized Control Trials Examining Perioperative Chemotherapy and Postoperative Adjuvant Chemotherapy for Resectable Colorectal Liver Metastasis. Ann Surg Oncol 27, 4271–4272 (2020). https://doi.org/10.1245/s10434-020-08809-8

Download citation